23
Jan

Much of the focus in biotech’s recent boom has been on the ease with which companies are making their way onto Wall Street. And, over the past week, a host of drug developers illustrated the benefits of being a publicly traded company, raising roughly $2.7 billion in follow-on offerings to bankroll R&D and potential acquisitions.

…read more

Source: Booming biotechs bank $2.7B in follow-on cash

    

0 No comments